(lp0
S"DURECT Corporation Announces Fourth Quarter and Full Year 2016 Financial ... PR Newswire  - Mar 14, 2017 ... ER , an investigational extended release pain relief drug based on DURECT's ORADUR technology. For more information, please visit www."
p1
aS"DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings ... PR Newswire  - Feb 24, 2017 CUPERTINO, Calif., Feb. 24, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's  fourth quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet ...To Buy Or Sell Durect Corporation  On Latest Analyst Consensus - Fiscal Standard"
p2
aS'DURECT Corporation Risk Points versus Health Care CML News - 9 hours ago This is a scatter plot analysis of the critical risk points from the option market for DURECT Corporation  compared to its own past and the Health Care ETF.'
p3
aS'DURECT Corporation Announces Third Quarter 2016 Financial Results and Update ... PR Newswire  - Oct 31, 2016 CUPERTINO, Calif., Oct. 31, 2016 /PRNewswire/ -- DURECT Corporation  announced today financial results for the third quarter of 2016.'
p4
aS"DURECT CORPORATION  Files An 8-K Results of Operations and ... Market Exclusive - Mar 14, 2017 Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries."
p5
aS"Here's Why DURECT Corporation Is Tanking Today Motley Fool - Sep 26, 2016 Investors in DURECT Corporation , a specialty pharmaceutical company that develops anti-abuse drug technology, are having a rough start to the trading week.Company Update : Here's Why DURECT Corporation Shares Fall 30% - Smarter AnalystDurect Corp.  Stock Tumbles on FDA Opioid Analgesic Drug Rejection - TheStreet.com"
p6
aS"DURECT Corporation Announces Update on DUR-928 Development Program PR Newswire  - Jan 30, 2017 30, 2017 /PRNewswire/ -- DURECT Corporation  today provided an update on the DUR-928 development program. DUR-928, our Epigenetic Regulator Program's lead product candidate, is an endogenous, small molecule, new chemical&nbsp;...DURECT says FDA wants more more drug-drug interaction data on lead candidate ... - Seeking Alpha"
p7
aS'Durect Corporation Seeking More Collaborations Seeking Alpha - Nov 15, 2016 Durect Corporation  is a small biopharmaceutical company  developing new therapeutics based on its Epigenetic Regulator Program  and proprietary long-acting drug delivery platforms.'
p8
aS"DURECT Corporation  Settles Into New 52-Week Low on February 08 Session Equities.com - Feb 8, 2017 Shares of DURECT Corporation  sank into a new 52-week low yesterday, and could be a company to watch at the open. The company's stock fell to as low as $0.98 yesterday after opening at $1.03."
p9
aS"Durect Corp. DRRX  Wall Street Journal - Feb 11, 2011 P/E Ratio : The Price to Earnings  ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period ..."
p10
a.